P170008/S064: EluNIR Ridaforolimus Eluting Coronary Stent System
FDA’s recorded scope: a shelf-life extension for a component in the delivery system
Explore this company’s associated devices, FDA decisions and regulatory history.

MedtechLedger currently links 6 FDA records to the applicant name Medinol, Ltd.. 1 entry is a PMA supplement. 5 entries are 30-day notices. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Aug 7, 2025 to Aug 6, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code NIQ appears in 6 of the 6 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P170008, with 6 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes.
Applicant mailing address recorded by FDA: Kiryat Atidim, Bldg. 8, P.O.B. 58165, Tel Aviv, 6158101. Recorded on P170008/S064, decision dated Aug 6, 2026.
FDA’s recorded scope: a shelf-life extension for a component in the delivery system
FDA’s recorded scope: a shelf-life extension of absorbers used in the packaging of the stent systems
FDA’s recorded scope: a shelf-life extension of the Carbosil material used in coating process
FDA’s recorded scope: a sampling plan that reduces sample size of the incoming inspections for raw materials and components of the EluNIR-PERL Ridaforolimus Eluting Coronary Stent System
FDA’s recorded scope: increasing hold time in manufacturing steps
Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medinol, Ltd. | PMA supplement | Aug 6, 2026 | FDA | |
| Medinol, Ltd. | PMA supplement | Mar 26, 2026 | FDA | |
| Medinol, Ltd. | PMA supplement | Feb 4, 2026 | FDA | |
| Medinol, Ltd. | PMA supplement | Oct 2, 2025 | FDA | |
| Medinol, Ltd. | PMA supplement | Aug 15, 2025 | FDA | |
| Medinol, Ltd. | PMA supplement | Aug 7, 2025 | FDA |
Source updated Nov 9, 2026. Retrieved Nov 20, 2026.